Maddalena Adorno

Maddalena Adorno has a diverse work experience that spans various roles and industries. In 2018, they co-founded Dorian Therapeutics and served as the CEO. The company focuses on combating cellular senescence and developing therapeutics to address aging-related stem cell pathways. Maddalena is currently an instructor at Stanford Continuing Studies since 2021. Maddalena was also a member of StartX in 2019. From 2009 to 2018, Maddalena worked at Stanford University School of Medicine as a research scientist, Siebel Scholar, and post-doc in stem cells and cancer stem cells. Additionally, they were a scientific co-founder at StemGuard Therapeutics Inc. from 2014 to 2017.

Maddalena Adorno's education history is as follows:

In 2018, they attended Y Combinator and studied S18 YC Bio.

From 2009 to 2014, they attended Stanford University School of Medicine and completed a Post-doc in Stem Cells and Cancer Stem Cells at the Institute for Stem Cells and Regenerative Medicine.

Between 2005 and 2008, they studied at Università degli Studi di Padova and obtained a PhD in Bioscience.

During the same period from 2005 to 2008, they also attended Università degli Studi di Verona and completed MD Pre-Clinical Education for three years.

Before their medical studies, they completed their MS in Medical Biotechnology at Università degli Studi di Padova, although the specific start year is not provided.